[go: up one dir, main page]

AR132497A1 - Combination of amorphous OBICETRAPIB and SGLT2 inhibitor - Google Patents

Combination of amorphous OBICETRAPIB and SGLT2 inhibitor

Info

Publication number
AR132497A1
AR132497A1 ARP240101021A ARP240101021A AR132497A1 AR 132497 A1 AR132497 A1 AR 132497A1 AR P240101021 A ARP240101021 A AR P240101021A AR P240101021 A ARP240101021 A AR P240101021A AR 132497 A1 AR132497 A1 AR 132497A1
Authority
AR
Argentina
Prior art keywords
obicetrapib
sglt2 inhibitor
disorder
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
ARP240101021A
Other languages
Spanish (es)
Inventor
Michael Harvey Davidson
Marc Ditmarsch
Johannes Jacob Pieter Kastelein
Sheng Cui
Andreas Ren Rtheli
Christopher J Borths
Muneki Kishida
Original Assignee
Newamsterdam Pharma B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Newamsterdam Pharma B V filed Critical Newamsterdam Pharma B V
Publication of AR132497A1 publication Critical patent/AR132497A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)

Abstract

Se proporciona en la presente una composición farmacéutica que comprende sal de calcio amorfa de obicetrapib y al menos un inhibidor de SGLT2, o una sal farmacéuticamente aceptable del mismo. También se proporcionan formas de dosificación que incluyen la misma. En algunas formas de forma de realización, la forma de dosificación es una forma de dosificación sólida, como un comprimido. También se proporcionan procesos para la preparación de formulaciones de dosis fijas de obicetrapib cálcico amorfo y un inhibidor de SGTL2, y métodos para utilizar las mismas en el tratamiento de un trastorno metabólico (por ejemplo, diabetes de tipo 2) o cardiometabólico. También se proporcionan métodos para tratar o prevenir un trastorno metabólico o un trastorno cardiometabólico en un sujeto que tiene o está en riesgo de desarrollar un trastorno metabólico o un trastorno cardiometabólico, que comprenden: administrar una cantidad terapéuticamente eficaz de obicetrapib, o una sal farmacéuticamente aceptable del mismo; y una cantidad terapéuticamente eficaz de al menos un inhibidor de SGLT2, o una sal farmacéuticamente aceptable del mismo.Provided herein is a pharmaceutical composition comprising obicetrapib amorphous calcium salt and at least one SGLT2 inhibitor, or a pharmaceutically acceptable salt thereof. Also provided are dosage forms including the same. In some embodiments, the dosage form is a solid dosage form, such as a tablet. Also provided are processes for preparing fixed-dose formulations of obicetrapib amorphous calcium and an SGLT2 inhibitor, and methods of using the same in the treatment of a metabolic (e.g., type 2 diabetes) or cardiometabolic disorder. Also provided are methods of treating or preventing a metabolic disorder or a cardiometabolic disorder in a subject having or at risk of developing a metabolic disorder or a cardiometabolic disorder, comprising: administering a therapeutically effective amount of obicetrapib, or a pharmaceutically acceptable salt thereof; and a therapeutically effective amount of at least one SGLT2 inhibitor, or a pharmaceutically acceptable salt thereof.

ARP240101021A 2023-04-24 2024-04-23 Combination of amorphous OBICETRAPIB and SGLT2 inhibitor AR132497A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202363497891P 2023-04-24 2023-04-24

Publications (1)

Publication Number Publication Date
AR132497A1 true AR132497A1 (en) 2025-07-02

Family

ID=91129723

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP240101021A AR132497A1 (en) 2023-04-24 2024-04-23 Combination of amorphous OBICETRAPIB and SGLT2 inhibitor

Country Status (4)

Country Link
KR (1) KR20250172894A (en)
AR (1) AR132497A1 (en)
TW (1) TW202446389A (en)
WO (1) WO2024226537A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2023303916A1 (en) * 2022-07-05 2025-01-30 Newamsterdam Pharma B.V. Salts of obicetrapib and processes for their manufacture and intermediates thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA71994C2 (en) 1999-08-31 2005-01-17 Kissei Pharmaceutical Glucopyranosyloxypyrazole derivatives, a pharmaceutical composition containing these derivatives and intermediate compounds for the preparation thereof
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
US7053060B2 (en) 2000-11-30 2006-05-30 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing the same and intermediates in the production thereof
KR100701437B1 (en) 2000-12-28 2007-03-30 깃세이 야쿠힌 고교 가부시키가이샤 Glucopyranosyloxypyrazole derivatives and pharmaceutical uses thereof
KR100945455B1 (en) 2002-03-22 2010-03-05 깃세이 야쿠힌 고교 가부시키가이샤 Crystallization of Glucopyranosyloxybenzyl Benzene Derivatives
DE10231370B4 (en) 2002-07-11 2006-04-06 Sanofi-Aventis Deutschland Gmbh Thiophene glycoside derivatives, medicaments containing these compounds and methods of making these medicaments
WO2004080990A1 (en) 2003-03-14 2004-09-23 Astellas Pharma Inc. C-glycoside derivatives and salts thereof
EA015104B1 (en) 2003-08-01 2011-06-30 Мицубиси Танабе Фарма Корпорейшн Novel compounds having inhibitory activity against sodium-dependant transporter
JP4181605B2 (en) 2004-03-16 2008-11-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Glucopyranosyl-substituted phenyl derivatives, pharmaceuticals containing the compounds, and uses and production methods thereof
UA90269C2 (en) 2004-04-02 2010-04-26 Мицубиси Танабе Фарма Корпорейшн Tetrahydroquinoline derivatives and a process for preparing the same
JP2008524162A (en) 2004-12-16 2008-07-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Glucopyranosyl-substituted benzene derivative, drug containing the compound, use thereof and production method thereof
US7723309B2 (en) 2005-05-03 2010-05-25 Boehringer Ingelheim International Gmbh Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
UA91546C2 (en) 2005-05-03 2010-08-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх Crystalline form of 1-chloro-4-(я-d-glucopyranos-1-yl)-2-[4-((s)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
AR056195A1 (en) 2005-09-15 2007-09-26 Boehringer Ingelheim Int PROCEDURES TO PREPARE DERIVATIVES OF (ETINIL-BENCIL) -BENZENE REPLACED GLUCOPYRANOSIL AND INTERMEDIATE COMPOUNDS OF THE SAME
US7745414B2 (en) 2006-02-15 2010-06-29 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture
TWI370818B (en) 2006-04-05 2012-08-21 Astellas Pharma Inc Cocrystal of c-glycoside derivative and l-proline
EP2019679B1 (en) 2006-05-23 2018-06-20 Theracos, Inc. Glucose transport inhibitors and methods of use
US7919598B2 (en) 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
TWI403516B (en) 2006-07-27 2013-08-01 Chugai Pharmaceutical Co Ltd To replace spirocyclic alcohol derivatives, and its use as a therapeutic agent for diabetes
US8039441B2 (en) 2006-08-15 2011-10-18 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as SGLT inhibitors and process for their manufacture
EP2086991A1 (en) 2006-10-27 2009-08-12 Boehringer Ingelheim International GmbH CRYSTALLINE FORM OF 4-(ß-D-GLUCOPYRANOS-1-YL)-1-METHYL-2-[4-((S)-TETRAHYDROFURAN-3-YLOXY)-BENZYL]-BENZENE, A METHOD FOR ITS PREPARATION AND THE USE THEREOF FOR PREPARING MEDICAMENTS
US7879806B2 (en) 2006-11-06 2011-02-01 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzyl-benzonitrile derivates, medicaments containing such compounds, their use and process for their manufacture
UY30730A1 (en) 2006-12-04 2008-07-03 Mitsubishi Tanabe Pharma Corp CRYSTAL FORM OF HEMIHYDRATE 1- (B (BETA) -D-GLUCOPYRANOSIL) -4-METHYL-3- [5- (4-FLUOROPHENYL) -2-TIENYLMETHYL] BENZENE
AR065809A1 (en) 2007-03-22 2009-07-01 Bristol Myers Squibb Co PHARMACEUTICAL FORMULATIONS CONTAINING AN SGLT2 INHIBITOR
CN101801371B (en) 2007-09-10 2012-11-28 詹森药业有限公司 Process for the preparation of compounds useful as SGLT inhibitors
PT2395983T (en) * 2009-02-13 2020-07-03 Boehringer Ingelheim Int Pharmaceutical composition comprising a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof
WO2014008374A2 (en) * 2012-07-06 2014-01-09 Thetis Pharmaceuticals Llc Combination therapies comprising metformin salts and antihyperglycemia agents or antihyperlipidemia agents
EP3708158A1 (en) * 2019-03-11 2020-09-16 Hartis-Pharma SA Allosteric regulators of hemoglobin useful in the treatment of sickle cell trait

Also Published As

Publication number Publication date
KR20250172894A (en) 2025-12-09
TW202446389A (en) 2024-12-01
WO2024226537A1 (en) 2024-10-31
WO2024226537A9 (en) 2025-03-27

Similar Documents

Publication Publication Date Title
ECSP20069416A (en) TREATMENT OF SUPURATIVE HYDRADENITIS USING JAK INHIBITORS
MX2019012884A (en) COMBINATION THERAPY.
CO2022013777A2 (en) Use of agents for the treatment of respiratory conditions
AR105712A1 (en) QUICK ACTION INSULIN COMPOSITIONS
ECSP045430A (en) COMBINATION THERAPY FOR CANCER TREATMENT
UY35624A (en) USE OF HIGH DOSE PRIDOPIDINE TO TREAT HUNTINGTON'S DISEASE
IL300151A (en) Combinations for cancer treatment
AR048431A1 (en) GALENIC FORMULATIONS OF ORGANIC COMPOUNDS
BR112014004741A2 (en) at least one chemical entity; pharmaceutical composition; use of a therapeutically effective amount of at least one chemical entity; packaged pharmaceutical composition
ES2570401T3 (en) Methods of treatment using single doses of oritavancin
AR085662A1 (en) METHODS AND COMPOSITIONS TO TREAT HYPERURICEMIA AND METABOLIC DISORDERS ASSOCIATED WITH HYPERURICEMIA
BRPI0415953A (en) oral controlled release dosage formulation, method of treating a disorder, set of controlled release dosage forms and method for administering the formulation
AR039164A1 (en) VENLAFAXINE SALTS OF LOW WATER SOLUBILITY
MX2021015543A (en) PYRIMIDINE DERIVATIVE THAT INHIBITS THE GROWTH OF CANCER CELLS AND MEDICINAL USE OF THE SAME.
MX2021014161A (en) Methods of treating sjã–gren's syndrome using a bruton's tyrosine kinase inhibitor.
AR127247A1 (en) CYCLOPENTYLPYRAZOLE CDK2 INHIBITORS
CL2021003312A1 (en) Composition comprising pridopidine and an analog thereof for the treatment of huntington's disease and its symptoms.
MX2025005378A (en) Methods for the treatment of cardiovascular disease
AR046036A1 (en) RISEDRONATE COMPOSITIONS AND METHODS FOR USE
AR132497A1 (en) Combination of amorphous OBICETRAPIB and SGLT2 inhibitor
AR119033A1 (en) METHODS FOR TREATING VIRUS-ASSOCIATED CANCERS WITH HISTONE DEACETYLASE INHIBITORS
MX2024005237A (en) Compound having btk protein degradation activity, and medical uses thereof.
CL2021000627A1 (en) Pharmaceutical compositions suitable for joint release and their use in the treatment of joint pain
CO6400019A1 (en) PHARMACEUTICAL COMPOSITION THAT INCLUDES RACETAM AND CARNITINE AND PROCESS FOR PREPARATION
MX2024008330A (en) Obicetrapib and sglt2 inhibitor combination